object
assess
effect
three
wntbcatenin
pathway
inhibitorsinhibitor
bcatenin
icat
niclosamid
prolifer
primari
cultur
human
uterin
leiomyoma
cell
design
prospect
studi
human
leiomyoma
cell
obtain
myomectomi
hysterectomi
set
univers
research
laboratori
patient
women
n
age
year
undergo
surgeri
intervent
adenovir
icat
overexpress
treatment
vari
concentr
niclosamid
main
outcom
measur
cell
prolifer
cell
death
wntcatenin
target
gene
express
report
gene
regul
bcatenin
level
cellular
local
result
inhibitor
bcatenin
niclosamid
inhibit
wntbcatenin
pathway
activ
exert
antiprolif
effect
primari
cultur
human
leiomyoma
cell
conclus
three
wntcatenin
pathway
inhibitor
specif
block
human
leiomyoma
growth
prolifer
suggest
canon
wnt
pathway
may
potenti
therapeut
target
treatment
uterin
leiomyoma
find
provid
rational
preclin
clinic
evalu
icat
niclosamid
candid
antitumor
agent
uterin
leiomyoma
fertil
steril
u
terin
leiomyoma
common
pelvic
tumor
women
benign
smoothmuscl
tumor
origin
myometrium
uterin
leiomyoma
occur
approxim
caucasian
women
african
american
women
age
year
caus
excess
uterin
bleed
anemia
recurr
pregnanc
loss
preterm
labor
pelvic
discomfort
urinari
incontin
approxim
case
recent
report
uliprist
acet
control
excess
bleed
due
leiomyoma
reduc
size
tumor
preoper
uliprist
acet
noninferior
oncemonthli
leuprolid
acet
control
uterin
bleed
significantli
less
like
caus
hot
flash
howev
leiomyoma
still
common
indic
hysterectomi
approxim
hysterectomi
myomectomi
thousand
select
uterinearteri
embol
highintens
focus
ultrasound
procedur
perform
annual
unit
state
remov
destroy
uterin
leiomyoma
annual
econom
burden
tumor
estim
billion
billion
thu
need
discov
new
treatment
modal
select
overexpress
constitut
activ
bcatenin
uterin
mesenchym
embryon
develop
adult
give
rise
leiomyomalik
tumor
uteru
femal
mice
suggest
signal
wntbcatenin
seem
play
role
somat
stem
cell
function
myometrium
uterin
leiomyoma
tissu
wnt
signal
frizzl
fzd
receptor
lead
stabil
cytosol
bcatenin
transloc
nucleu
result
activ
transcript
factor
tcell
factorlymphoid
enhanc
factor
tcflef
absenc
pathway
stimul
complex
consist
axin
glycogen
synthas
kinas
adenomat
polyposi
coli
promot
bcatenin
phosphoryl
subsequ
proteolyt
degrad
wnt
signal
import
embryon
develop
also
activ
stem
cell
dysregul
wnt
signal
common
denomin
varieti
tumor
wntactiv
mutat
present
mani
cancer
includ
colon
cancer
hepatocellular
carcinoma
melanoma
nonsmallcel
lung
cancer
ovarian
endometrioid
cancer
wnt
ligand
inhibitor
shown
affect
growth
surviv
colon
cancer
cell
suggest
target
wnt
pathway
receptor
may
feasibl
therapeut
approach
interf
downstream
proteinprotein
interact
inde
block
canon
wnt
activ
colorect
wntderegul
cancer
caus
cellcycl
arrest
g
phase
lead
tumor
cell
growth
inhibit
well
establish
wntbcatenin
signal
promot
cell
prolifer
particularli
epithelialderiv
cancer
stem
cell
popul
whether
bcatenin
signal
drove
smoothmuscl
cell
prolifer
activ
similar
gene
target
epitheli
cell
unclear
recent
report
lung
fibroblast
prolifer
control
bcatenin
signal
recent
year
sever
class
small
molecul
shown
act
wnt
inhibitor
exert
inhibitori
effect
variou
level
wnt
signal
pathway
three
small
moleculesinhibitor
bcatenin
icat
niclosamid
shown
strongli
specif
reduc
level
activ
bcatenin
vitro
inhibit
bcatenin
stabil
downstream
bcatenin
signal
tcflef
report
activ
studi
hypothes
molecul
also
inhibit
wntbcatenin
signal
reduc
growth
prolifer
human
leiomyoma
cell
test
effect
molecul
primari
cultur
leiomyoma
cell
women
undergo
hysterectomi
myomectomi
leiomyoma
goal
establish
antitumor
properti
molecul
potenti
candid
develop
leiomyoma
sampl
obtain
surgeri
women
age
rang
year
undergo
hysterectomi
myomectomi
use
leiomyoma
deriv
patient
without
receiv
hormon
treatment
deidentifi
patient
inform
collect
includ
age
weight
height
race
day
last
menstrual
cycl
pariti
use
oral
contracept
written
inform
consent
obtain
patient
use
human
tissu
approv
institut
review
board
human
research
northwestern
univers
chicago
illinoi
none
women
previou
histori
uterin
cancer
sampl
confirm
histopatholog
examin
free
malign
isol
leiomyoma
cell
use
techniqu
previous
describ
use
asmooth
muscl
actin
protein
express
gene
mutat
marker
leiomyoma
cell
leiomyoma
cell
cultur
flatbottom
plate
dulbecco
modifi
eagl
medium
dmem
life
technolog
contain
fetal
bovin
serum
grown
humidifi
atmospher
co
c
freshli
cultur
leiomyoma
cell
treat
mmoll
nacl
sigma
baselin
bcatenin
condit
mmoll
licl
sigma
inhibit
activ
therebi
activ
bcatenin
cell
prolifer
assay
leiomyoma
cell
incub
day
variou
concentr
niclosamid
mmoll
sigma
mmoll
r
system
reagent
dilut
dimethyl
sulfoxid
dmso
sigma
control
cell
treat
dmso
leiomyoma
cell
cultur
flatbottom
plate
infect
adenoviru
encod
green
fluoresc
protein
adgfp
adicat
hour
mycicat
complementari
dna
provid
tetsu
akiyama
univers
tokyo
reengin
vector
biolab
encod
bicistron
messeng
rna
translat
mycicat
gfp
protein
adicat
myc
intern
ribosom
entri
sitegfp
adgfp
virus
use
control
icat
treatment
suppli
tong
chuan
univers
chicago
infect
effici
confirm
visual
gfp
express
live
cell
leiomyoma
cell
without
adenovir
infect
use
control
viral
transduct
cell
incub
day
cell
prolifer
measur
inner
salt
mt
assay
cell
titer
aqueou
one
solut
cell
prolifer
assay
promega
use
accord
manufactur
instruct
prolifer
measur
optic
densiti
od
nm
synergyht
plate
reader
biotek
instrument
leiomyoma
cell
death
assay
previous
describ
lactat
dehydrogenas
ldh
activ
measur
use
cytotox
detect
kit
roch
od
read
use
synergyht
plate
reader
softwar
biotek
instrument
total
rna
extract
use
rneasi
mini
kit
qiagen
accord
manufactur
instruct
complementari
dna
synthes
mg
rna
use
qscript
cdna
supermix
quanta
bioscienc
quantit
realtim
revers
transcriptionpolymeras
chain
reaction
rtpcr
wnt
target
gene
nake
perform
use
abi
life
technolog
power
sybr
green
pcr
master
mix
life
technolog
cycl
cycl
consist
denatur
c
follow
minut
anneal
c
size
amplicon
bp
bp
respect
specif
pcr
product
analyz
use
builtin
melt
curv
analysi
tool
dna
product
identifi
sampl
express
level
normal
housekeep
gene
encod
dehydrogenas
gapdh
determin
compar
threshold
cycl
ct
method
leiomyoma
cell
transfect
tcf
optim
luciferas
promot
plasmid
topflash
contain
four
consensu
tcfbind
site
upstream
minim
cfo
promot
fopflash
contain
four
mutant
tcfbind
site
kindli
provid
h
clever
utrecht
netherland
use
lipofectamin
invitrogen
thymidin
kinaserenilla
plasmid
ng
cotransfect
normal
luciferas
valu
transfect
effici
cell
treat
niclosamid
without
licl
hour
transfect
cell
solubil
day
transfect
use
dualluciferas
assay
kit
promega
luciferas
activ
quantifi
synergyht
plate
reader
biotek
instrument
firefli
luciferas
read
first
normal
read
correspond
renilla
luciferas
read
normal
transfect
effici
adjust
topflash
read
normal
correspond
adjust
fopflash
read
account
background
read
topflash
construct
indirect
immunofluoresc
stain
perform
describ
previous
background
fluoresc
determin
appli
secondari
conjug
antibodi
alon
replac
primari
antibodi
nonimmun
serum
slide
success
stain
bcatenin
antibodi
clone
bd
bioscienc
follow
incub
secondari
antibodi
label
alexa
fluor
dye
molecular
probe
life
technolog
imag
collect
use
confoc
laser
scan
system
lsm
karl
zeiss
evalu
activ
canon
wnt
signal
intracellular
level
cadherinfre
bcatenin
determin
pulldown
assay
use
glutathion
stransferas
gst
icat
previous
describ
end
treatment
period
cell
harvest
solubil
nonion
deterg
buffer
nonidet
mm
tri
ph
mm
nacl
mm
ethylenediaminetetraacet
acid
includ
proteas
inhibitor
centrifug
g
cellular
bcatenin
affinityprecipit
use
gsticat
immobil
glutathionecoupl
sepharos
sigma
wash
buffer
mm
tri
ph
mm
nacl
mm
ethylenediaminetetraacet
acid
nonidet
mgml
leupeptin
aprotinin
subject
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
immunoblot
analysi
use
bcatenin
icat
polyclon
santa
cruz
biotechnolog
bactin
antibodi
clone
sigma
experi
repeat
use
cell
least
three
subject
follow
statist
analysi
data
express
mean
ae
sd
probabl
p
valu
calcul
use
student
test
valu
p
consid
statist
signific
leiomyoma
prolifer
thought
critic
step
leiomyoma
tumorigenesi
address
contribut
wntbcatenin
signal
phenotyp
use
cultur
human
leiomyoma
cell
adenovirus
adicat
inhibit
wntbcatenin
signal
human
leiomyoma
cell
transduc
adgfp
adicat
hour
viral
transduct
cell
incub
day
cell
prolifer
measur
mt
assay
n
leiomyoma
cell
transduc
adicat
exhibit
significantli
lower
prolifer
compar
adgfp
transduc
cell
supplement
fig
avail
onlin
observ
reduct
prolifer
icat
overexpress
due
diffus
cellular
toxic
becais
adgfp
adicat
transduc
leiomyoma
cell
show
differ
ldh
level
compar
control
group
tx
supplement
fig
leiomyoma
cell
n
treat
licl
hour
induc
bcatenin
transcript
wnt
pathway
target
gene
supplement
fig
subsequ
adenovir
express
icat
significantli
inhibit
liclstimul
gene
express
measur
realtim
pcr
adicat
transduc
cell
without
licl
treatment
messeng
rna
express
level
similar
adgfp
transduc
cell
niclosamid
shown
inhibit
wnt
pathway
activ
colorect
cancer
cell
human
leiomyoma
cell
n
treat
dmso
increas
concentr
niclosamid
day
analysi
mt
assay
niclosamid
inhibit
prolifer
leiomyoma
cell
dosedepend
manner
fig
b
observ
reduct
prolifer
niclosamid
treatment
relat
decreas
cell
surviv
ldh
activ
level
similar
leiomyoma
cell
treatment
group
fig
activ
wntbcatenin
pathway
result
stimul
tcflef
transcript
factor
bind
tcf
element
promot
target
gene
analyz
effect
niclosamid
wntbcatenin
signal
human
leiomyoma
cell
transfect
cell
n
luciferas
report
construct
consist
four
copi
tcf
element
topflash
treat
cell
increas
concentr
niclosamid
presenc
licl
expect
licl
treatment
activ
bcatenin
upregul
topflash
report
activ
effect
blunt
treatment
increas
concentr
niclosamid
fig
niclosamid
treatment
also
downregul
liclinduc
express
human
leiomyoma
cell
n
fig
activ
wnt
signal
pathway
result
accumul
bcatenin
nucleu
follow
heterodim
format
tcf
activ
tcfdepend
transcript
examin
effect
niclosamid
subcellular
local
bcatenin
human
leiomyoma
cell
n
fig
treatment
licl
induc
nuclear
accumul
bcatenin
wherea
treatment
niclosamid
block
baselin
liclinduc
bcatenin
nuclear
transloc
evalu
amount
bcatenin
human
leiomyoma
cell
n
gsticat
pulldown
assay
expect
bcatenin
level
significantli
lower
niclosamidetr
leiomyoma
cell
compar
vehicletr
cell
fig
tankyras
protein
poli
adenosin
diphosphateribos
polymeras
activ
tankyras
shown
involv
wnt
signal
pathway
tankyras
bind
directli
axin
member
destruct
complex
involv
bcatenin
degrad
inhibit
tankyras
stabil
axin
increas
activ
destruct
complex
promot
degrad
bcatenin
tankyras
inhibitor
therebi
inhibit
wntbcatenin
signal
human
leiomyoma
cell
n
treat
dmso
increas
concentr
day
analysi
mt
assay
inhibit
prolifer
leiomyoma
cell
dosedepend
manner
fig
b
reduc
prolifer
observ
due
effect
diffus
cell
toxic
ldh
activ
level
across
treatment
group
fig
analyz
effect
wntbcatenin
signal
human
leiomyoma
cell
n
transfect
cell
tcf
report
construct
topflash
fopflash
treat
cell
increas
concentr
presenc
licl
inhibit
liclinduc
tcf
report
activ
dosedepend
manner
fig
also
downregul
liclinduc
express
human
leiomyoma
cell
measur
realtim
quantit
pcr
fig
significantli
inhibit
liclstimul
nuclear
transloc
bcatenin
human
leiomyoma
cell
fig
gsticat
pulldown
assay
reveal
remark
decreas
activ
bcatenin
upon
treatment
human
leiomyoma
cell
fig
mani
bcatenin
target
gene
involv
cell
prolifer
hypothes
enhanc
wntbcatenin
signal
leiomyoma
cell
contribut
leiomyoma
tumor
growth
human
notabl
human
leiomyoma
cell
primari
cultur
contain
substanti
level
gsticatprecipit
bcatenin
baselin
fig
activ
bcatenin
signal
spontan
observ
number
primari
cell
cultur
test
whether
inhibit
wntbcatenin
signal
alter
human
leiomyoma
cell
prolifer
result
show
icat
niclosamid
specif
inhibit
canon
wntbcatenin
signal
decreas
wntdepend
transcript
primari
cultur
human
leiomyoma
cell
result
reduc
cell
growth
prolifer
vitro
find
add
exist
bodi
knowledg
critic
role
wntbcatenin
signal
pathway
play
develop
adult
tissu
homeostasi
also
tumor
develop
fibrogenesi
select
delet
bcatenin
uterin
mesenchym
embryon
develop
significantli
reduc
uterin
size
replac
adipocyt
thu
complet
disrupt
normal
myometri
smoothmuscl
differenti
regener
convers
select
overexpress
constitut
activ
bcatenin
uterin
mesenchym
embryon
develop
adult
give
rise
leiomyomalik
tumor
uteru
femal
mice
suggest
bcatenin
play
key
role
stem
cell
renew
differenti
smoothmuscl
phenotyp
observ
myometri
leiomyoma
tissu
wntbcatenin
pathway
may
promis
target
new
therapeut
uterin
leiomyoma
monoclon
tumor
growth
neoplasm
occur
via
clonal
expans
singl
cell
rais
possibl
intervent
target
mechan
underli
cell
expans
may
particularli
effect
treatment
uterin
leiomyoma
compon
wnt
pathway
prime
drug
develop
target
particularli
access
plasma
membran
receptor
frizzl
vuga
et
al
found
increas
fibroblast
prolifer
noncanon
bcatenintcfindepend
signal
mechan
indic
canon
noncanon
wnt
may
contribut
tumorigenesi
given
wntbcatenin
target
gene
celltyp
cellcontext
depend
identifi
wntbcateninregul
target
gene
human
leiomyoma
requir
similar
unbias
approach
leiomyoma
contain
specif
genet
mutat
found
suggest
transform
normal
myocyt
abnorm
myocyt
requir
point
genesi
leiomyoma
bind
directli
bcatenin
regul
canon
wnt
signal
interestingli
express
activ
bcatenin
markedli
elev
leiomyoma
mutat
vs
without
mutat
observ
point
mechan
involv
mutat
wntbcatenin
activ
support
cell
prolifer
uterin
leiomyoma
tissu
interestingli
size
number
bcatenindriven
leiomyomalik
tumor
increas
pariti
mice
suggest
exposur
steroid
hormon
may
interact
activ
bcatenin
acceler
tumorigenesi
moreov
activ
bcatenin
induc
express
transform
growth
induc
prolifer
extracellular
matrix
format
human
leiomyoma
tissu
known
bcatenin
signal
antagon
adipogenesi
inhibit
adipogen
transcript
factor
ccaatenhanc
bind
proteina
peroxisom
proliferatoractiv
receptor
g
two
percent
leiomyoma
contain
adipocyt
undergon
metaplasia
suggest
aberr
bcatenin
signal
affect
tumor
initi
tumor
mainten
uterin
leiomyoma
mechan
action
niclosamid
thought
intern
downregul
wnt
pathway
intermediari
common
usag
antihelminth
believ
uncoupl
oxid
phosphoryl
recent
found
effect
low
micromolar
concentr
prevent
synthesi
corona
viru
protein
tissu
cultur
model
sever
acut
respiratori
syndrom
known
function
bcatenin
control
ubiquitin
ultim
degrad
proteasom
possibl
mechan
niclosamid
function
might
effect
either
ubiquitin
proteolyt
pathway
caus
degrad
bcatenin
recent
studi
found
inhibit
poli
adpribos
polymeras
parp
domain
tankyras
destabil
polyadpribosyl
parsyl
present
studi
show
topflash
assay
niclosamid
inhibit
wnt
pathway
activ
leiomyoma
cell
attempt
rule
nonspecif
toxic
effect
niclosamid
wntbcatenin
signal
human
leiomyoma
cell
effect
liclinduc
wntbcatenintcfrespons
report
activ
cell
transient
cotransfect
prlcmv
either
topflash
fopflash
firefli
luciferas
report
plasmid
treatment
licl
andor
hour
report
plasmidcondit
transfect
cell
plate
triplic
well
data
report
mean
topflash
activ
normal
transfect
effici
prl
construct
background
fopflash
ae
sd
six
independ
experi
b
inhibit
liclinduc
wntbcatenin
target
gene
express
human
leiomyoma
cell
cell
treat
nacl
licl
activ
bcatenin
induc
downstream
express
wntbcatenin
target
gene
total
rna
extract
determin
express
quantit
realtim
pcr
result
express
mean
express
ae
sd
rel
gapdh
four
independ
experi
c
treatment
effect
nuclear
local
bcatenin
human
leiomyoma
cell
indirect
immunofluoresc
perform
leiomyoma
cell
treatment
nacl
licl
dmso
use
antibcatenin
antibodi
green
follow
hoechst
nuclear
counterstain
blue
merg
imag
bcatenin
green
hoechst
blue
stain
also
shown
repres
imag
five
independ
experi
scale
bar
mm
arrowhead
indic
nucleu
treatment
bcatenin
level
human
leiomyoma
cell
wholecel
lysat
leiomyoma
cell
treat
dmso
affin
precipit
gsticat
isol
cytosol
bcatenin
activ
bcatenin
bound
gsticat
probe
antibcatenin
antibodi
repres
immunoblot
three
independ
sampl
shown
actin
load
control
taken
input
p
cell
use
ldh
assay
notic
morpholog
chang
cell
treatment
thu
studi
need
assess
nonspecif
toxic
effect
compound
diseas
healthi
tissu
niclosamid
administ
oral
referenc
report
specul
system
treatment
work
wnt
canon
signal
highli
activ
diseas
tissu
therefor
suscept
effect
drug
compar
healthi
tissu
allow
lower
dose
administ
howev
reduc
undesir
side
effect
alway
goal
develop
novel
therapi
consequ
avoid
offtarget
effect
might
attract
develop
vagin
deliveri
system
deliv
therapeut
local
avoid
system
complic
summari
show
downregul
wntbcatenin
signal
via
icat
niclosamid
antitumor
effect
primari
cultur
human
leiomyoma
cell
vitro
studi
demonstr
sustain
activ
wntbcatenin
signal
leiomyoma
cell
enhanc
activ
associ
leiomyoma
format
prolifer
howev
given
wntbcatenin
signal
control
cellfat
decis
throughout
develop
often
control
balanc
progenitor
cell
descend
specul
cell
serv
progenitor
leiomyoma
may
key
target
wntbcatenin
signal
leiomyoma
tumorigenesi
